INHIBITION OF HEPATITIS B VIRUS REPLICATION BY VIDARABINE MONOPHOSPHATE CONJUGATED WITH LACTOSAMINATED SERUM ALBUMIN
- 1 July 1988
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 332 (8601) , 13-15
- https://doi.org/10.1016/s0140-6736(88)92946-7
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Effects of adenine arabinoside on serum and intrahepatic replicative forms of duck hepatitis B virus in chronic infectionHepatology, 1987
- Drug targeting in antiviral chemotherapyBiochemical Pharmacology, 1986
- Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection.Gut, 1985
- Comparative efficacy of adenine arabinoside 5′ monophosphate and prednisone withdrawal followed by adenine arabinoside 5′ monophosphate in the treatment of chronic active hepatitis type BGastroenterology, 1985
- Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combinationAntimicrobial Agents and Chemotherapy, 1982
- Hepatocyte targeting of adenine‐9‐β‐D‐arabinofuranoside 5′‐monophosphate (ara‐AMP) coupled to lactosaminated albuminFEBS Letters, 1981
- VidarabineDrugs, 1980
- HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine.BMJ, 1978
- Effect of vidarabine on chronic hepatitis B virus infectionJAMA, 1978
- Activity of albumin conjugates of 5-fluorodeoxyuridine and cytosine arabinoside on poxviruses as a lysosomotropic approach to antiviral chemotherapyNature, 1976